| Literature DB >> 25294798 |
Daniela Alejandra Quinteros1, Luis Ignacio Tártara2, Santiago Daniel Palma2, Ruben Hilario Manzo2, Daniel Alberto Allemandi2.
Abstract
A novel ophthalmic formulation based on the ionic complexation between Eudragit E 100 (EU) and flurbiprofen (FB) is proposed. The selected complex composition, named EU-FBH50 Cl50 , had the basic groups of EU completely neutralized with equal molar amounts of FB and HCl. This complex, obtained in the solid state, exhibited a high aqueous compatibility producing a colloidal dispersion with a high positive electrokinetic potential, in which more than 99% of FB was ionically condensed with EU. In bicompartimental Franz cells, FB diffusion from the complex was very slow. However, dispersion in 0.9% NaCl increased the FB release through an ionic exchange, providing an optimal constant rate of delivery. Corneal FB permeation from 0.1% EU-FBH50 -Cl50 dispersed in 0.9% NaCl solution was substantially more effective compared with 0.1% FB solution, EU-FBH50 -Cl50 (Dex), or Tolerane(®) (a marketed formulation). This complex formulation was shown to be innocuous for rabbit ocular tissues because no irritant effects were evidenced.Entities:
Keywords: Controlled release; Eudragit; Permeability; Polymeric drug delivery systems; complex; flurbiprofen; ophthalmic solution
Mesh:
Substances:
Year: 2014 PMID: 25294798 DOI: 10.1002/jps.24153
Source DB: PubMed Journal: J Pharm Sci ISSN: 0022-3549 Impact factor: 3.534